bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Table 3 from miRNA-141, Downregulated in Pancreatic Cancer, Inhibits Cell Proliferation and Invasion by Directly Targeting MAP4K4
Authors: Zhao Gang , Wang Bo , Liu Yang , Zhang Jun-gang , Deng Shi-chang , Qin Qi , Tian Kui , Li Xiang , Zhu Shuai , Niu Yi , Gong Qiong , Wang Chun-you
Published: April 2023

PDF - 60KB, Immunohistochemical staining analysis shows different expressions of MAP4K4 in pancreatic cancer tissues and their adjacent noncancerous tissues.
Supplementary Figure 4 from Combinatorial Therapy Using Dovitinib and ICI182.780 (Fulvestrant) Blocks Tumoral Activity of Endometrial Cancer Cells
Authors: Eritja Nuria , Domingo Mónica , Dosil Maria Alba , Mirantes Cristina , Santacana Maria , Valls Joan , Llombart-Cussac Antonio , Matias-Guiu Xavier , Dolcet Xavier
Published: April 2023

PDF - 86K, Endometrial cancer cell lines were treated with ICI 182,780 at 100nM. Total protein lysates were extracted at indicated times after treatment and were subjected to western blot for the expression of ERalpha. Tubulin is shown as at loading control.
Supplementary Table 1 from miRNA-141, Downregulated in Pancreatic Cancer, Inhibits Cell Proliferation and Invasion by Directly Targeting MAP4K4
Authors: Zhao Gang , Wang Bo , Liu Yang , Zhang Jun-gang , Deng Shi-chang , Qin Qi , Tian Kui , Li Xiang , Zhu Shuai , Niu Yi , Gong Qiong , Wang Chun-you
Published: April 2023

PDF - 5KB, The primer sequences of genes.
Supplementary Figure 1 from Combinatorial Therapy Using Dovitinib and ICI182.780 (Fulvestrant) Blocks Tumoral Activity of Endometrial Cancer Cells
Authors: Eritja Nuria , Domingo Mónica , Dosil Maria Alba , Mirantes Cristina , Santacana Maria , Valls Joan , Llombart-Cussac Antonio , Matias-Guiu Xavier , Dolcet Xavier
Published: April 2023

PDF - 762K, Four ECCs (IK, AN3CA, MFE-296 and HEC-1A) were treated with Dovitinib (0.05-0.1-0.5-1-2.5 micromol/L) for 48 and 72 hours, and cell viability was assessed by MTT assay. B) Three ECCs (AN3CA, MFE-296 and HEC-1A) were treated with 0.5 micromol/L of Dovitinib or vehicle for 72 h, after quantification of the percentage of BrdU-positive cells was assessed.
Supplementary materials, Tables S1-S2 from Three-Dimensional Cell Culture-Based Screening Identifies the Anthelmintic Drug Nitazoxanide as a Candidate for Treatment of Colorectal Cancer
Authors: Senkowski Wojciech , Zhang Xiaonan , Olofsson Maria Hägg , Isacson Ruben , Höglund Urban , Gustafsson Mats , Nygren Peter , Linder Stig , Larsson Rolf , Fryknäs Mårten
Published: April 2023

Supplementary materials, Tables S1-S2. Supplementary Table S1. List of the 12 3D-selective screening hits, Supplementary Table S2. Structures and properties of the five final hit compounds.
Supplementary Figure 1 from miRNA-141, Downregulated in Pancreatic Cancer, Inhibits Cell Proliferation and Invasion by Directly Targeting MAP4K4
Authors: Zhao Gang , Wang Bo , Liu Yang , Zhang Jun-gang , Deng Shi-chang , Qin Qi , Tian Kui , Li Xiang , Zhu Shuai , Niu Yi , Gong Qiong , Wang Chun-you
Published: April 2023

PDF - 1662KB, Supplementary Figure S1. Overexpression of MiR-141 promotes G1 phase arrest, apoptosis and chemosensitivity of MiaPaCa-2 cells. (A) Flow cytometry analysis showed that the cell cycle of MiaPaCa-2 was arrested at the G1 phase after upregulation of miR-141. The histogram indicates the percentage of cells in the G1 phase. (B) MiR-141 induced apoptosis of MiaPaCa-2 cells. (C) The bar graphs for cell cycle and apoptosis counting. (C) Overexpression of miR-141 sensitized MiaPaCa-2 cells to 5-Fu and Gemcitabine. Different concentrations were applied to the cells for 48 h and cell viability was measured by MTT assay. (D) Western blot analysis indicated that upregulation of miR-141 resulted in significant downregulation of the invasion associated proteins MMP-2 and MMP-9, the cell cycle related protein cyclinD1 and the anti-apoptotic protein Bcl-2, as well as overexpression of the pro-apoptotic protein Bax.* P<0.05, **P<0.01. *** P<0.001.
Supplementary Figure 5 from Preclinical Evaluation of the Supercritical Extract of Azadirachta Indica (Neem) Leaves In Vitro and In Vivo on Inhibition of Prostate Cancer Tumor Growth
Authors: Wu Qiang , Kohli Manish , Bergen H. Robert. , Cheville John C. , Karnes R. Jeffrey , Cao Hong , Young Charles Y.F. , Tindall Donald J. , McNiven Mark A. , Donkena Krishna Vanaja
Published: April 2023

PDF - 64K, Mass spectrometric analysis of SENL fractions 9, 11, and 12 obtained from HPLC. The total ion chromatogram retention time and the mass spectrum of individual peaks for the fractions 9, 11, and 12 are depicted in the panel A to C, respectively.
Supplementary Figure 2 from In Vitro and In Vivo Activity of the Low-Immunogenic Antimesothelin Immunotoxin RG7787 in Pancreatic Cancer
Authors: Hollevoet Kevin , Mason-Osann Emily , Liu Xiu-fen , Imhof-Jung Sabine , Niederfellner Gerhard , Pastan Ira
Published: April 2023

PDF - 207K, A: Untreated KLM-1 tumors stain strongly for mesothelin. B-D: Mesothelin expression is not affected by treatment with RG7787, paclitaxel or both. IHC was done by Histoserv, Inc. according to a standard protocol. Representative pictures (10X) are shown.
Supplementary Figure 4 from Preclinical Evaluation of the Supercritical Extract of Azadirachta Indica (Neem) Leaves In Vitro and In Vivo on Inhibition of Prostate Cancer Tumor Growth
Authors: Wu Qiang , Kohli Manish , Bergen H. Robert. , Cheville John C. , Karnes R. Jeffrey , Cao Hong , Young Charles Y.F. , Tindall Donald J. , McNiven Mark A. , Donkena Krishna Vanaja
Published: April 2023

PDF - 69K, Mass spectrometric analysis of SENL fractions 5, 6, and 7 obtained from HPLC. The total ion chromatogram retention time and the mass spectrum of individual peaks for the fractions 5, 6, and 7 are depicted in the panel A to C, respectively.
Supplementary Figure 1 from In Vitro and In Vivo Activity of the Low-Immunogenic Antimesothelin Immunotoxin RG7787 in Pancreatic Cancer
Authors: Hollevoet Kevin , Mason-Osann Emily , Liu Xiu-fen , Imhof-Jung Sabine , Niederfellner Gerhard , Pastan Ira
Published: April 2023

PDF - 66K, A: SYTOX Dead Cell Stains allows to gate out viable cells from a representative dissociated KLM-1 tumor. B: In the subpopulation of viable cells, cell doublets are excluded. C: CD71+ cells (=human KLM-1 tumor cells) are gated out of the subpopulation of viable single cells. D: Based on the Alexa-647 background signal in the CD71+ cells of an untreated tumor (not shown), a gate is set and the percentage of Alexa-647+ cells in an RG7787-Alexa647-treated tumor is determined.
Supplementary Figure S5 from Synergy of Radiotherapy and a Cancer Vaccine for the Treatment of HPV-Associated Head and Neck Cancer
Authors: Mondini Michele , Nizard Mevyn , Tran Thi , Mauge Laetitia , Loi Mauro , Clémenson Céline , Dugue Delphine , Maroun Pierre , Louvet Emilie , Adam Julien , Badoual Cécile , Helley Dominique , Dransart Estelle , Johannes Ludger , Vozenin Marie-Catherine , Perfettini Jean-Luc , Tartour Eric , Deutsch Eric
Published: April 2023

NG2 and ICAM-1 staining are increased by combined treatment
Supplementary Figure 9 from Computational Repositioning and Preclinical Validation of Pentamidine for Renal Cell Cancer
Authors: Zerbini Luiz Fernando , Bhasin Manoj K. , de Vasconcellos Jaira F. , Paccez Juliano D. , Gu Xuesong , Kung Andrew L. , Libermann Towia A.
Published: April 2023

PDF file - 2473KB, Analysis of functions and canonical pathway enrichment for up- and down-regulated genes in response to pentamidine treatment.
Supplementary Figure 1 from Computational Repositioning and Preclinical Validation of Pentamidine for Renal Cell Cancer
Authors: Zerbini Luiz Fernando , Bhasin Manoj K. , de Vasconcellos Jaira F. , Paccez Juliano D. , Gu Xuesong , Kung Andrew L. , Libermann Towia A.
Published: April 2023

PDF file - 202KB, Flowchart of study design.
Supplementary Figure 9 from A Naturally Derived Small Molecule Disrupts Ligand-Dependent and Ligand-Independent Androgen Receptor Signaling in Human Prostate Cancer Cells
Authors: Amin Karishma S. , Jagadeesh Shankar , Baishya Gakul , Rao Paruchuri G. , Barua Nabin C. , Bhattacharya Samir , Banerjee Partha P.
Published: April 2023

PDF file - 95K, Determination of nuclear-cytoplasmic distribution of phosphorylated AR Ser 81 in the presence of DHT and mahanine.
Supplementary Table 2 from FAK Inhibition Disrupts a β5 Integrin Signaling Axis Controlling Anchorage-Independent Ovarian Carcinoma Growth
Authors: Tancioni Isabelle , Uryu Sean , Sulzmaier Florian J. , Shah Nina R. , Lawson Christine , Miller Nichol L.G. , Jean Christine , Chen Xiao Lei , Ward Kristy K. , Schlaepfer David D.
Published: April 2023

PDF file - 70K, Background information on the breast and ovarian carcinoma cell lines used in this study.
Supplementary Table 1 from FAK Inhibition Disrupts a β5 Integrin Signaling Axis Controlling Anchorage-Independent Ovarian Carcinoma Growth
Authors: Tancioni Isabelle , Uryu Sean , Sulzmaier Florian J. , Shah Nina R. , Lawson Christine , Miller Nichol L.G. , Jean Christine , Chen Xiao Lei , Ward Kristy K. , Schlaepfer David D.
Published: April 2023

PDF file - 44K, Antibodies, DNA plasmids, and probe sets used in this study.
Supplementary Figure 5 from A Naturally Derived Small Molecule Disrupts Ligand-Dependent and Ligand-Independent Androgen Receptor Signaling in Human Prostate Cancer Cells
Authors: Amin Karishma S. , Jagadeesh Shankar , Baishya Gakul , Rao Paruchuri G. , Barua Nabin C. , Bhattacharya Samir , Banerjee Partha P.
Published: April 2023

PDF file - 223K, Effects of mahanine on AR degradation in VCaP and LNCaP-C4-2B cells.
Supplementary Figure 5 from FAK Inhibition Disrupts a β5 Integrin Signaling Axis Controlling Anchorage-Independent Ovarian Carcinoma Growth
Authors: Tancioni Isabelle , Uryu Sean , Sulzmaier Florian J. , Shah Nina R. , Lawson Christine , Miller Nichol L.G. , Jean Christine , Chen Xiao Lei , Ward Kristy K. , Schlaepfer David D.
Published: April 2023

PDF file - 138K, Integrin surface expression in HEY beta5 integrin knockdown cells.
Supplementary Figure 4 from A Naturally Derived Small Molecule Disrupts Ligand-Dependent and Ligand-Independent Androgen Receptor Signaling in Human Prostate Cancer Cells
Authors: Amin Karishma S. , Jagadeesh Shankar , Baishya Gakul , Rao Paruchuri G. , Barua Nabin C. , Bhattacharya Samir , Banerjee Partha P.
Published: April 2023

PDF file - 29K, Effect of mahanine on ligand-independent activation of AR in VCaP cells.
Supplementary Figure 4 from FAK Inhibition Disrupts a β5 Integrin Signaling Axis Controlling Anchorage-Independent Ovarian Carcinoma Growth
Authors: Tancioni Isabelle , Uryu Sean , Sulzmaier Florian J. , Shah Nina R. , Lawson Christine , Miller Nichol L.G. , Jean Christine , Chen Xiao Lei , Ward Kristy K. , Schlaepfer David D.
Published: April 2023

PDF file - 66K, qPCR verification of beta5 transcripts.
Supplementary Figure 1 from FAK Inhibition Disrupts a β5 Integrin Signaling Axis Controlling Anchorage-Independent Ovarian Carcinoma Growth
Authors: Tancioni Isabelle , Uryu Sean , Sulzmaier Florian J. , Shah Nina R. , Lawson Christine , Miller Nichol L.G. , Jean Christine , Chen Xiao Lei , Ward Kristy K. , Schlaepfer David D.
Published: April 2023

PDF file - 894K, FAK and pY397 FAK immunostaining of human tissue array.
Supplementary Figure Legends from New Blocking Antibodies against Novel AGR2–C4.4A Pathway Reduce Growth and Metastasis of Pancreatic Tumors and Increase Survival in Mice
Authors: Arumugam Thiruvengadam , Deng Defeng , Bover Laura , Wang Huamin , Logsdon Craig D. , Ramachandran Vijaya
Published: April 2023

Extracellular rAGR2-mediated functions, Candidate receptors binding and silencing, Silencing C4.4A reduced basal and rAGR2-mediated functions, Effects of AGR2 are mediated by C4.4A interacting with integrin beta 1, Monoclonal antibodies developed bind respectively to AGR2 and C4.4A proteins and blocked their functions, In Vivo treatment with AGR2/C4.4A antibodies reduced tumor volume are described as the experiment is conducted.
Supplementary Figure 1 from Zoledronic Acid Reverses the Epithelial–Mesenchymal Transition and Inhibits Self-Renewal of Breast Cancer Cells through Inactivation of NF-κB
Authors: Schech Amanda J. , Kazi Armina A. , Gilani Rabia A. , Brodie Angela H.
Published: April 2023

PDF file - 45K, Zoledronic acid increases epithelial phenotype of Hs578t cells.
Supplementary Table 5 from Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition
Authors: Davis Sally J. , Sheppard Karen E. , Anglesio Michael S. , George Joshy , Traficante Nadia , Fereday Sian , Intermaggio Maria P. , Menon Usha , Gentry-Maharaj Aleksandra , Lubinski Jan , Gronwald Jacek , Pearce Celeste Leigh , Pike Malcolm C. , Wu Anna , Kommoss Stefan , Pfisterer Jacobus , du Bois Andreas , Hilpert Felix , Ramus Susan J. , Bowtell David D.L. , Huntsman David G. , Pearson Richard B. , Simpson Kaylene J. , Campbell Ian G. , Gorringe Kylie L.
Published: April 2023

MetaCore analysis results
Supplementary Table 2 from Chemotherapy-Regulated microRNA-125–HER2 Pathway as a Novel Therapeutic Target for Trastuzumab-Mediated Cellular Cytotoxicity in Small Cell Lung Cancer
Authors: Yagishita Shigehiro , Fujita Yu , Kitazono Satoru , Ko Ryo , Nakadate Yusuke , Sawada Takeshi , Kitamura Yuka , Shimoyama Tatsu , Maeda Yoshiharu , Takahashi Fumiyuki , Takahashi Kazuhisa , Tamura Tomohide , Koizumi Fumiaki
Published: April 2023

The primer sequences for qRT-PCR analysis
Supplementary Figure 2 from Chemotherapy-Regulated microRNA-125–HER2 Pathway as a Novel Therapeutic Target for Trastuzumab-Mediated Cellular Cytotoxicity in Small Cell Lung Cancer
Authors: Yagishita Shigehiro , Fujita Yu , Kitazono Satoru , Ko Ryo , Nakadate Yusuke , Sawada Takeshi , Kitamura Yuka , Shimoyama Tatsu , Maeda Yoshiharu , Takahashi Fumiyuki , Takahashi Kazuhisa , Tamura Tomohide , Koizumi Fumiaki
Published: April 2023

WB analysis for downstream intracellular signaling of HER2 after exposure to CDDP (IC50 concentration), trastuzumab (1 μg/ml), and CDDP plus trastuzumab.
Supplementary Data from Doxycycline as an Inhibitor of the Epithelial-to-Mesenchymal Transition and Vasculogenic Mimicry in Hepatocellular Carcinoma
Authors: Meng Jie , Sun Baocun , Zhao Xiulan , Zhang Danfang , Zhao Xueming , Gu Qiang , Dong Xueyi , Zhao Nan , Liu Peimei , Liu Yanrong
Published: April 2023

Supplementary Data. Table S1 shows the information of antibodies used in this study. Table S2 shows the results of immunohistochemistry.
Supplementary Figure 4 from Src Mediates Cigarette Smoke–Induced Resistance to Tyrosine Kinase Inhibitors in NSCLC Cells
Authors: Filosto Simone , Baston David S. , Chung Samuel , Becker Cathleen R. , Goldkorn Tzipora
Published: April 2023

PDF file - 1448K, Phosphorylation of Y845-EGFR does not control the CS-driven aberrant EGFR activation, nor the subsequent TKI resistance. A. Serum starved NIH-3T3 cells stably over expressing either WT or Y845F MT EGFR were incubated (or not) with 1microM AG1478 for 30' and then treated, or not (-), with EGF or CS, as before for additional 30'. EGFR was IPed from the total cell lysates and IBed for total receptor and for auto-phosphorylation on Y1173.
Supplementary Figure 1 from Src Mediates Cigarette Smoke–Induced Resistance to Tyrosine Kinase Inhibitors in NSCLC Cells
Authors: Filosto Simone , Baston David S. , Chung Samuel , Becker Cathleen R. , Goldkorn Tzipora
Published: April 2023

PDF file - 967K, CS strongly activates Src kinase. A. NIH-3T3 cells stably expressing the L858R MT EGFR were exposed to EGF or CS for 30 min., as before, and activation / phosphorylation level of Src (p-Y416 Src) as well as total Src protein levels were measured in cell lysates (by IB). The graphic in B represents the quantification of Src activation levels in NIH-3T3 obtained from 3 independent experiments and and from CHO cells from one experiment; * = p < 0.05. C. Serum-starved CHO cells transiently over-expressing either WT or KD (K721A) MT EGFR were treated with EGF or CS, as before. 30 microg of proteins from the cell lysates were analyzed by IB for activation levels of EGFR and c-Src, as indicated. The graphic in D represents the quantification of Src activation levels, as shown in C.
Supplementary Figure 1 from Concordance of Genomic Alterations between Primary and Recurrent Breast Cancer
Authors: Meric-Bernstam Funda , Frampton Garrett M. , Ferrer-Lozano Jaime , Yelensky Roman , Pérez-Fidalgo Jose A. , Wang Ying , Palmer Gary A. , Ross Jeffrey S. , Miller Vincent A. , Su Xiaoping , Eroles Pilar , Barrera Juan Antonio , Burgues Octavio , Lluch Ana M. , Zheng Xiaofeng , Sahin Aysegul , Stephens Philip J. , Mills Gordon B. , Cronin Maureen T. , Gonzalez-Angulo Ana M.
Published: April 2023

PDF - 168K, Detailed analysis of matched primary and recurrent/metastatic breast tumors.
Supplementary Figure Legends from Culture Dimensionality Influences the Resistance of Glioblastoma Stem-like Cells to Multikinase Inhibitors
Authors: Fernandez-Fuente Gonzalo , Mollinedo Pilar , Grande Lara , Vazquez-Barquero Alfonso , Fernandez-Luna Jose L.
Published: April 2023

PDF - 60K, Legends for Supplementary Figures 1 through 3.
Down-regulation of ANT2 protein levels by shRNA from Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non–Small Cell Lung Cancer
Authors: Jang Ji-Young , Kim Yong-goo , Nam Soo Jeong , Keam Bhumsuk , Kim Tae Min , Jeon Yoon Kyung , Kim Chul Woo
Published: April 2023

At 24 h after transfection with ANT2-specific shRNA or sc shRNA, Western blotting was performed to determine the levels of ANT2 and actin as a loading control.
Supplementary Figure 4 from Effect of Niclosamide on Basal-like Breast Cancers
Authors: Londoño-Joshi Angelina I. , Arend Rebecca C. , Aristizabal Laura , Lu Wenyan , Samant Rajeev S. , Metge Brandon J. , Hidalgo Bertha , Grizzle William E. , Conner Michael , Forero-Torres Andres , LoBuglio Albert F. , Li Yonghe , Buchsbaum Donald J.
Published: April 2023

PDF file - 96KB, Supplementary Figure S4. Wnt/beta-catenin signaling proteins in LRP6 KD cells. Western blot for expression of Wnt/beta-catenin signaling proteins in adherent 2LMP shRNA LRP6 knockdown cells compared to shRNA control cells.
Supplementary Figure 4 from Targeting Protein Tyrosine Phosphatase SHP2 for the Treatment of PTPN11-Associated Malignancies
Authors: Yu Bing , Liu Wei , Yu Wen-Mei , Loh Mignon L. , Alter Shawn , Guvench Olgun , MacKerell Alexander D. , Tang Li-Da , Qu Cheng-Kui
Published: April 2023

PDF file - 65 KB, Effect of Triton X-100 on the function of #220-324 in inhibiting SHP2 activity.
Supplementary Tables 3 through 6 from The Use of Olaparib (AZD2281) Potentiates SN-38 Cytotoxicity in Colon Cancer Cells by Indirect Inhibition of Rad51-Mediated Repair of DNA Double-Strand Breaks
Authors: Tahara Makiko , Inoue Takeshi , Sato Futoshi , Miyakura Yasuyuki , Horie Hisanaga , Yasuda Yoshikazu , Fujii Hirofumi , Kotake Kenjiro , Sugano Kokichi
Published: April 2023

PDF - 83K, Table S3-S5: Data of cell diameters measured using the Scepter 2.0 cell counter in each treatment as shown in Supplementary Fig. S1, Fig. 5 and Supplementary Fig. S6. Table S6: Data of blood samples of SW1116 xenografted mice.
Supplementary Figure 2 from Targeting Protein Tyrosine Phosphatase SHP2 for the Treatment of PTPN11-Associated Malignancies
Authors: Yu Bing , Liu Wei , Yu Wen-Mei , Loh Mignon L. , Alter Shawn , Guvench Olgun , MacKerell Alexander D. , Tang Li-Da , Qu Cheng-Kui
Published: April 2023

PDF file - 111 KB, Predicted binding pose of #220-324 with SHP2 phosphatase.
Supplementary Figure 4 from Inhibition of Akt Reverses the Acquired Resistance to Sorafenib by Switching Protective Autophagy to Autophagic Cell Death in Hepatocellular Carcinoma
Authors: Zhai Bo , Hu Fengli , Jiang Xian , Xu Jun , Zhao Dali , Liu Bing , Pan Shangha , Dong Xuesong , Tan Gang , Wei Zheng , Qiao Haiquan , Jiang Hongchi , Sun Xueying
Published: April 2023

PDF file - 327K, Supplementary Fig. S4.Akt inhibition or depletion synergizes with sorafenib to inhibit cell growth by regulating autophagic and apoptotic pathways in sorafenib-resistant HCC cells.
Supplementary Materials and Methods and Supplementary Figures 1 through 9 from Novel Neutralizing Hedgehog Antibody MEDI-5304 Exhibits Antitumor Activity by Inhibiting Paracrine Hedgehog Signaling
Authors: Michaud Neil R. , Wang Youzhen , McEachern Kristen A. , Jordan Jerold J. , Mazzola Anne Marie , Hernandez Axel , Jalla Sanjoo , Chesebrough Jon W. , Hynes Mark J. , Belmonte Matthew A. , Wang Lidong , Kang Jaspal S. , Jovanović Jelena , Laing Naomi , Jenkins David W. , Hurt Elaine , Liang Meina , Frantz Christopher , Hollingsworth Robert E. , Simeone Diane M. , Blakey David C. , Bedian Vahe
Published: April 2023

Supplementary Materials and Methods; Supplementary Figure S1. Binding kinetics of hedgehog antibodies to human and mouse hedgehog proteins using surface plasmon resonance. Supplementary Figure S2. Hedgehog ligands stimulate mGLI1 reporter activity and osteoblast differentiation in a dose-dependent manner. Supplementary Figure S3. Selective inhibition of mGLI1 or mPTC1 induction in C3H10T1/2 cells by hedgehog antibodies. Supplementary Figure S4. MEDI-5304 inhibits GLI1 expression in Colo205 xenograft stromal cells but not tumor cells. Supplementary Figure S5. Hedgehog pathway component RNA expression in primary pancreatic tumor explant model P479 and effects of MEDI-5304 on tumorspheres derived from pancreatic explant model 947. Supplementary Figure S6. Pharmacokinetics of MEDI-5304 in rats. Supplementary Figure S7. Exploratory toxicology of MEDI-5304 in rats. Supplementary Figure S8. Pharmacokinetics of MEDI-5304 from preliminary toxicology study in cynomolgus monkeys. Supplementary Figure S9. Pharmacodynamics of MEDI-5304 in cynomolgus monkeys.
Supplementary Figure 5 from Metformin Blocks Melanoma Invasion and Metastasis Development in AMPK/p53-Dependent Manner
Authors: Cerezo Michaël , Tichet Mélanie , Abbe Patricia , Ohanna Mickaël , Lehraiki Abdelali , Rouaud Florian , Allegra Maryline , Giacchero Damien , Bahadoran Philippe , Bertolotto Corine , Tartare-Deckert Sophie , Ballotti Robert , Rocchi Stéphane
Published: April 2023

PDF - 121K, Mewo melanoma cells (mutated for p53) were treated for 24h with 10mM of metformin or PBS and labeled with Cell Tracker Green and injected via the tail vein of nude mice.
Supplementary Figure 3 from Metformin Blocks Melanoma Invasion and Metastasis Development in AMPK/p53-Dependent Manner
Authors: Cerezo Michaël , Tichet Mélanie , Abbe Patricia , Ohanna Mickaël , Lehraiki Abdelali , Rouaud Florian , Allegra Maryline , Giacchero Damien , Bahadoran Philippe , Bertolotto Corine , Tartare-Deckert Sophie , Ballotti Robert , Rocchi Stéphane
Published: April 2023

PDF - 155K, (A) Mel501 melanoma cells stably transfected with a shRNA against p53 were treated 24h with metformin (at the indicated concentrations) or PBS, lysed and analysed by Western-blot with N-Cadherin, p53, Sparc and Slug antibodies. HSP90 was used for loading control. (B)Invasion assay in coated Boyden chambers with Mel501 melanoma cells stably transfected with a shRNA against p53, treated 24h with metformin (at the indicated concentrations) or PBS.
Supplementary Materials and Methods, Supplementary Figures 1 through 8 with legends, and Supplementary Tables 1 to 5 from ATF4 Gene Network Mediates Cellular Response to the Anticancer PAD Inhibitor YW3-56 in Triple-Negative Breast Cancer Cells
Authors: Wang Shu , Chen Xiangyun Amy , Hu Jing , Jiang Jian-kang , Li Yunfei , Chan-Salis Ka Yim , Gu Ying , Chen Gong , Thomas Craig , Pugh B. Franklin , Wang Yanming
Published: April 2023

The supplementary data contain Supplementary Materials and Methods, Supplementary Figures 1 through 8 with legends, and Supplementary Tables 1 to 5. Supplementary Fig. 1. YW3-56 inhibits growth of p53 wild type and mutant cells. Supplementary Fig. 2. PAD inhibitor YW3-56 inhibits PAD4 in HL-60 derived granulocytic cells. Supplementary Fig. 3. Effects of YW3-56 on the ATF4 and AMPK gene networks. Supplementary Fig. 4. ATF4 directly binds to the SESN2 and DDIT4 promoters. Supplementary Fig. 5. ChIP-exo analyses of ATF4 binding to its target sites. Supplementary Figure 6. mTOR inhibition following thapsigargin induced ER stress. Supplementary Figure 7. Effects of ATF4, SESN2, and DDIT4 depletion on cell growth and YW3-56 mediated cell killing. Supplementary Figure 8. Features of YW3-56 induced cell death. Supplementary Table 1. List of qRT-PCR and ChIP-qPCR primers used in this research work. Supplementary Table 2. Genes with altered expression after YW3-56 treatment. (see Excel spreadsheet) Supplementary Table 3. List of ATF4 associated genes. (see Excel spreadsheet) Supplementary Table 4. List of CEBPB associated genes. (see Excel spreadsheet) Supplementary Table 5. Expression changes of ATF4 and CEBPB candidate genes after YW3-56 treatment.
Supplementary Figure 1 from Elevated Cyclin D1 Expression Is Predictive for a Benefit from TPF Induction Chemotherapy in Oral Squamous Cell Carcinoma Patients with Advanced Nodal Disease
Authors: Zhong Lai-Ping , Zhu Dong-Wang , William William N. , Liu Ying , Ma Jie , Yang Cheng-Zhe , Yang Xiao , Wang Li-Zhen , Li Jiang , Myers Jeffrey N. , Lee J. Jack , Zhang Chen-Ping , Zhang Zhi-Yuan
Published: April 2023

PDF file - 10421K, Immunohistochemical staining for cyclin D1, negative (A), weak positive (B), and strong positive staining (C), original magnification �200.
Supplementary Figure 2 from Antitumor Effects in Gastrointestinal Stromal Tumors Using Photodynamic Therapy with a Novel Glucose-Conjugated Chlorin
Authors: Tanaka Mamoru , Kataoka Hiromi , Yano Shigenobu , Ohi Hiromi , Moriwaki Kazuhiro , Akashi Haruo , Taguchi Takahiro , Hayashi Noriyuki , Hamano Shingo , Mori Yoshinori , Kubota Eiji , Tanida Satoshi , Joh Takashi
Published: April 2023

PDF file - 311KB, GIST-T1 cells were loaded with H2TFPC (1 microM (A) or 20 microM (B) for 4 h and labeled with MitoTracker Green, LysoTracker Green, NBD-C6 ceramide Green, or ER-Tracker Green. The images were obtained by confocal microscopy.
Supplementary Figure 5 from The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models
Authors: Foster Paul , Yamaguchi Kyoko , Hsu Pin P. , Qian Fawn , Du Xiangnan , Wu Jianming , Won Kwang-Ai , Yu Peiwen , Jaeger Christopher T. , Zhang Wentao , Marlowe Charles K. , Keast Paul , Abulafia Wendy , Chen Jason , Young Jenny , Plonowski Artur , Yakes F. Michael , Chu Felix , Engell Kelly , Bentzien Frauke , Lam Sanh T. , Dale Stephanie , Yturralde Olivia , Matthews David J. , Lamb Peter , Laird A. Douglas
Published: April 2023

Dose-response relationships for inhibition of PI3K pathway signaling by XL147 in tumors.
Supplementary Figure 4 from The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models
Authors: Foster Paul , Yamaguchi Kyoko , Hsu Pin P. , Qian Fawn , Du Xiangnan , Wu Jianming , Won Kwang-Ai , Yu Peiwen , Jaeger Christopher T. , Zhang Wentao , Marlowe Charles K. , Keast Paul , Abulafia Wendy , Chen Jason , Young Jenny , Plonowski Artur , Yakes F. Michael , Chu Felix , Engell Kelly , Bentzien Frauke , Lam Sanh T. , Dale Stephanie , Yturralde Olivia , Matthews David J. , Lamb Peter , Laird A. Douglas
Published: April 2023

Effects of XL147 on PI3K Pathway Signaling in A549, MDA-MB-468 and LS174T cells.
Supplementary Methods, Tables 1 - 2, Figure Legend from Targeting Blockage of STAT3 in Hepatocellular Carcinoma Cells Augments NK Cell Functions via Reverse Hepatocellular Carcinoma–Induced Immune Suppression
Authors: Sun Xiaoxia , Sui Qiangjun , Zhang Cai , Tian Zhigang , Zhang Jian
Published: April 2023

PDF file - 130K, Supplementary Table 1 Fluorochrome-conjugated antibodies used in flow cytometry.; Supplementary Table 2 Primers used in PCR.
Supplemental Figure S2 from Angiotensin-(1-7) Decreases Cell Growth and Angiogenesis of Human Nasopharyngeal Carcinoma Xenografts
Authors: Pei Nana , Wan Renqiang , Chen Xinglu , Li Andrew , Zhang Yanling , Li Jinlong , Du Hongyan , Chen Baihong , Wei Wenjin , Qi Yanfei , Zhang Yi , Katovich Michael J. , Sumners Colin , Zheng Haifa , Li Hongwei
Published: April 2023

Supplemental Figure S2. AAV8 (Y733F)-CBA-Ang-(1-7) and AAV8 (Y733F)-CBA-eGFP mediated transduction of Ang-(1-7) fusion protein and eGFP in mouse liver.
Supplementary Figures 7 and 8 from MAP17 (PDZKIP1) Expression Determines Sensitivity to the Proteasomal Inhibitor Bortezomib by Preventing Cytoprotective Autophagy and NFκB Activation in Breast Cancer
Authors: Muñoz-Galván Sandra , Gutierrez Gabriel , Perez Marco , Carnero Amancio
Published: April 2023

Supplementary Figure S7 - MAP17 levels determine the sensitivity to bortezomib regulating autophagy. Cells were treated with the indicated drug concentrations and performed western blot as described (see Supplementary Methods). (A) levels of proteins of the autophagosomal markers LC3B (LC3-II), in T47D and MDA-MB-231 cells overexpressing MAP17 or expressing only empty vector. (B) Quantification of proteins from A, measured as the fold increase (from control untreated cells) of protein referred to a-tubulin. Supplementary Figure S8 - MAP17 overrexpression increases endogenous ROS. Quantification of intracellular ROS leves in T47D and MDA-MB-231 cell lines. Average and SD of three independent experiments are shown. ***, P<0.001 (Student's t-test).
Supplementary Figure 6 from MAP17 (PDZKIP1) Expression Determines Sensitivity to the Proteasomal Inhibitor Bortezomib by Preventing Cytoprotective Autophagy and NFκB Activation in Breast Cancer
Authors: Muñoz-Galván Sandra , Gutierrez Gabriel , Perez Marco , Carnero Amancio
Published: April 2023

Supplementary Figure S6 - MAP17 overexpression reduces NFKB levels in response to Bortezomib. (A) Immunofluorescence of T47D and (B) MDA-MB-231 cells overexpressing or not MAP17, and treated with increasing concentrations of Bortezomib. NFKB-p65 is shown in green and DAPI nuclear staining in blue. Quantification of NFKB-p65 fluorescent intensity from A and B, respectively, are shown below microscope images. Average and SD of at least 300 cells per each condition are shown.
Supplementary Figure 4 from Combination of Anti-HER3 Antibody MM-121/SAR256212 and Cetuximab Inhibits Tumor Growth in Preclinical Models of Head and Neck Squamous Cell Carcinoma
Authors: Jiang Ning , Wang Dongsheng , Hu Zhongliang , Shin Hyung Ju C. , Qian Guoqing , Rahman Mohammad Aminur , Zhang Hongzheng , Amin A.R.M. Ruhul , Nannapaneni Sreenivas , Wang Xiaojing , Chen Zhengjia , Garcia Gabriela , MacBeath Gavin , Shin Dong M. , Khuri Fadlo R. , Ma Jun , Chen Zhuo G. , Saba Nabil F.
Published: April 2023

PDF file - 143KB, The CM combination inhibits PI3K/AKT and ERK signaling pathways.
Supplementary Methods, Figure Legends, Tables 1 - 4, Figure 1 from UPARANT: A Urokinase Receptor–Derived Peptide Inhibitor of VEGF-Driven Angiogenesis with Enhanced Stability and In Vitro and In Vivo Potency
Authors: Carriero Maria Vincenza , Bifulco Katia , Minopoli Michele , Lista Liliana , Maglio Ornella , Mele Luigi , Di Carluccio Gioconda , De Rosa Mario , Pavone Vincenzo
Published: April 2023

PDF file - 234K, Table S1 - Stability in physiological solution of UPARANT. Table S2 - Blood Stability of UPARANT. Table S3. Proton Chemical Shifts, 3JNH-alphaCH Coupling Constants of UPARANT at 298 K. Table S4. Average backbone torsion angles of RERF as obtained from RMD simulation in vacuo at 300 K. Figure S1 - 1H NMR spectra and selected regions of the ROESY spectra of UPARANT.
Supplemental Table 2 from Targeted Blockade of JAK/STAT3 Signaling Inhibits Ovarian Carcinoma Growth
Authors: Gritsina Galina , Xiao Fang , O'Brien Shane W. , Gabbasov Rashid , Maglaty Marisa A. , Xu Ren-Huan , Thapa Roshan J. , Zhou Yan , Nicolas Emmanuelle , Litwin Samuel , Balachandran Siddharth , Sigal Luis J. , Huszar Dennis , Connolly Denise C.
Published: April 2023

Supplemental Table 2. Gene ontology (GO) enrichment categories.
Supplementary Methods, Supplementary Figures 1 through 4, and Supplementary Table 1 from Fatostatin Displays High Antitumor Activity in Prostate Cancer by Blocking SREBP-Regulated Metabolic Pathways and Androgen Receptor Signaling
Authors: Li Xiangyan , Chen Yi-Ting , Hu Peizhen , Huang Wen-Chin
Published: April 2023

PDF - 1143K, Supplementary Methods, Supplementary Figure Legends, Supplementary Figure S1. Chemical structure of fatostatin. Supplementary Figure S2. Fatostatin blocks nuclear abundance of SREBP-1 and SREBP-2 in LNCaP and C4-2B cells. Supplementary Figure S3. Fatostatin inhibits the transcriptional activity of SREBPs determined by the SREs (sterol regulatory elements)-luciferase (Luc) reporter assay. Supplementary Figure S4. Fatostatin blocks AR nuclear translocation in LNCaP and C4-2B cells. Supplementary Table S1. The Sequences of primers used for qRT-PCR.
Supplementary Figure 3 from Bcl-2/Bcl-xL Inhibition Increases the Efficacy of MEK Inhibition Alone and in Combination with PI3 Kinase Inhibition in Lung and Pancreatic Tumor Models
Authors: Tan Nguyen , Wong Maureen , Nannini Michelle A. , Hong Rebecca , Lee Leslie B. , Price Stephen , Williams Karen , Savy Pierre Pascal , Yue Peng , Sampath Deepak , Settleman Jeffrey , Fairbrother Wayne J. , Belmont Lisa D.
Published: April 2023

PDF file - 751K, Bliss Scores of A549 and H647 Across Dose Matrix. Percent inhibition relative to DMSO control was measured using CellTiterGlo. Bliss scores were calculated as described in the materials and methods
Supplementary Methods and Figure Legend from Discovery of a Novel Orally Active Small-Molecule gp130 Inhibitor for the Treatment of Ovarian Cancer
Authors: Xu Shili , Grande Fedora , Garofalo Antonio , Neamati Nouri
Published: April 2023

PDF file - 99K
Supplementary Table 2 from Inhibition of Homologous Recombination and Promotion of Mutagenic Repair of DNA Double-Strand Breaks Underpins Arabinoside–Nucleoside Analogue Radiosensitization
Authors: Magin Simon , Papaioannou Maria , Saha Janapriya , Staudt Christian , Iliakis George
Published: April 2023

Supplementary Table 2. Sensitizer enhancement ratios for different replication inhibitors
Supplementary Figure Legend from REST Negatively and ISGF3 Positively Regulate the Human STAT1 Gene in Melanoma
Authors: Amalraj James , Cutler Samuel J. , Ghazawi Ibtisam , Boyle Glen M. , Ralph Stephen J.
Published: April 2023

PDF file - 167K
Legends to supplemental material from Inhibition of Homologous Recombination and Promotion of Mutagenic Repair of DNA Double-Strand Breaks Underpins Arabinoside–Nucleoside Analogue Radiosensitization
Authors: Magin Simon , Papaioannou Maria , Saha Janapriya , Staudt Christian , Iliakis George
Published: April 2023

Legends to supplemental material. Word file containing all the legends to suppl. material
Supplementary Figure 1 from Epithelial-to-Mesenchymal Transition Mediates Docetaxel Resistance and High Risk of Relapse in Prostate Cancer
Authors: Marín-Aguilera Mercedes , Codony-Servat Jordi , Reig Òscar , Lozano Juan José , Fernández Pedro Luis , Pereira María Verónica , Jiménez Natalia , Donovan Michael , Puig Pere , Mengual Lourdes , Bermudo Raquel , Font Albert , Gallardo Enrique , Ribal María José , Alcaraz Antonio , Gascón Pere , Mellado Begoña
Published: April 2023

PDF - 265K, Biochemical-relapse analysis according to gene expression levels of markers differentially expressed in treated vs non-treated patients.
Supplementary Figure 2 from Ponatinib Induces Apoptosis in Imatinib-Resistant Human Mast Cells by Dephosphorylating Mutant D816V KIT and Silencing β-Catenin Signaling
Authors: Jin Bei , Ding Ke , Pan Jingxuan
Published: April 2023

PDF file - 185KB, The effect of Ponatinib on beta-catenin signaling.
Supplementary Figure 1 from Frequent Loss of NISCH Promotes Tumor Proliferation and Invasion in Ovarian Cancer via Inhibiting the FAK Signal Pathway
Authors: Li Jing , He Xiaoying , Dong Ruofan , Wang Yuan , Yu Jinjin , Qiu Haifeng
Published: April 2023

Representative electrophoresis images for promoter hypermethylation and LOH of NISCH.
Supplementary Figures 1-3 from Cosilencing of PKM-2 and MDR-1 Sensitizes Multidrug-Resistant Ovarian Cancer Cells to Paclitaxel in a Murine Model of Ovarian Cancer
Authors: Talekar Meghna , Ouyang Qijun , Goldberg Michael S. , Amiji Mansoor M.
Published: April 2023

Supplementary Figures 1-3. Supplementary Figure 1: Safety analysis in SKOV-3WT tumor bearing mice that had single and combination treatments of siRNA and PTX; Supplementary Figure 2: H&E staining for SKOV-3WT tumor bearing mice that had single and combination treatments of siRNA and PTX (A) Liver tissue, (B) Kidney and (C) Spleen; Supplementary Figure 3: Alteration in HA-PEI/PEG:EGF ratio on siMDR-1 transfection efficiency.
Supplementary Figures 1-7 from Bisphosphonates Inhibit Stellate Cell Activity and Enhance Antitumor Effects of Nanoparticle Albumin–Bound Paclitaxel in Pancreatic Ductal Adenocarcinoma
Authors: Gonzalez-Villasana Vianey , Rodriguez-Aguayo Cristian , Arumugam Thiruvengadam , Cruz-Monserrate Zobeida , Fuentes-Mattei Enrique , Deng Defeng , Hwang Rosa F. , Wang Huamin , Ivan Cristina , Garza Raul Joshua , Cohen Evan , Gao Hui , Armaiz-Pena Guillermo N. , del C. Monroig-Bosque Paloma , Philip Bincy , Rashed Mohammed H. , Aslan Burcu , Erdogan Mumin Alper , Gutierrez-Puente Yolanda , Ozpolat Bulent , Reuben James M. , Sood Anil K. , Logsdon Craig , Lopez-Berestein Gabriel
Published: April 2023

Supplementary Figures 1-7. Supplementary Figure 1. (A) Capan-2 animal protocol. Supplementary Figure 2. Effects of the combination of ZA with nab-paclitaxel on the mRNA levels of alpha-SMA and Rap1A in vivo. Supplementary Figure 3. (A) Reduction of pancreatic tumor volume by Gem alone or ZA alone. Supplementary Figure 4. Cell viability assessed by MTS assay. Supplementary Figure 5. Isobologram analysis. Supplementary Figure 6. Combination of ZA with nab-paclitaxel decrease fibronectin levels in vitro and laminin levels in vivo. Supplementary Figure 7. Mechanistic association of ZA and nab-paclitaxel.
Supplementary Figure Legends from Myostatin Neutralization Results in Preservation of Muscle Mass and Strength in Preclinical Models of Tumor-Induced Muscle Wasting
Authors: Smith Rosamund C. , Cramer Martin S. , Mitchell Pamela J. , Capen Andrew , Huber Lysiane , Wang Rong , Myers Laura , Jones Bryan E. , Eastwood Brian J. , Ballard Darryl , Hanson Jeff , Credille Kelly M. , Wroblewski Victor J. , Lin Boris K. , Heuer Josef G.
Published: April 2023

Supplementary Figure Legends
Supplementary Figure 6 from Myostatin Neutralization Results in Preservation of Muscle Mass and Strength in Preclinical Models of Tumor-Induced Muscle Wasting
Authors: Smith Rosamund C. , Cramer Martin S. , Mitchell Pamela J. , Capen Andrew , Huber Lysiane , Wang Rong , Myers Laura , Jones Bryan E. , Eastwood Brian J. , Ballard Darryl , Hanson Jeff , Credille Kelly M. , Wroblewski Victor J. , Lin Boris K. , Heuer Josef G.
Published: April 2023

Supplementary Figure 6. LY2495655 attenuates the loss of muscle weight normalized to brain weight in the PC3 tumor model.
Supplementary Table 4 from LY2606368 Causes Replication Catastrophe and Antitumor Effects through CHK1-Dependent Mechanisms
Authors: King Constance , Diaz H. Bruce , McNeely Samuel , Barnard Darlene , Dempsey Jack , Blosser Wayne , Beckmann Richard , Barda David , Marshall Mark S.
Published: April 2023

Supplementary Table S4. LY2606368-dependent chromosome fragmentation is not caused by caspase-dependent apoptosis
Supplementary Table 1 from LY2606368 Causes Replication Catastrophe and Antitumor Effects through CHK1-Dependent Mechanisms
Authors: King Constance , Diaz H. Bruce , McNeely Samuel , Barnard Darlene , Dempsey Jack , Blosser Wayne , Beckmann Richard , Barda David , Marshall Mark S.
Published: April 2023

Supplementary Table S1. Protein kinases tested for inhibition by LY2606368
Data Supplement from Nanolipolee-007, a Novel Nanoparticle-Based Drug Containing Leelamine for the Treatment of Melanoma
Authors: Gowda Raghavendra , Madhunapantula SubbaRao V. , Sharma Arati , Kuzu Omer F. , Robertson Gavin P.
Published: April 2023

Supplemental Figure S1. Leelamine hydrochloride salt is poorly soluble in saline. * Indicates the stock concentration of drug used in this report.
Figure S3 from Utilization of the Eμ-Myc Mouse to Model Heterogeneity of Therapeutic Response
Authors: Rempel Rachel E. , Jiang Xiaolei , Fullerton Paul , Tan Tuan Zea , Ye Jieru , Lau Jieying Amelia , Mori Seiichi , Chi Jen-Tsan , Nevins Joseph R. , Friedman Daphne R.
Published: April 2023

Figure S3: Stability of selected Eµ-Myc lymphoma clones after transplantation
Figure S1 from Utilization of the Eμ-Myc Mouse to Model Heterogeneity of Therapeutic Response
Authors: Rempel Rachel E. , Jiang Xiaolei , Fullerton Paul , Tan Tuan Zea , Ye Jieru , Lau Jieying Amelia , Mori Seiichi , Chi Jen-Tsan , Nevins Joseph R. , Friedman Daphne R.
Published: April 2023

Figure S1: Unsupervised analysis of gene expression data identifies two Eµ-Myc lymphoma clusters
Supplementary Figure 3 from NT113, a Pan-ERBB Inhibitor with High Brain Penetrance, Inhibits the Growth of Glioblastoma Xenografts with EGFR Amplification
Authors: Yoshida Yasuyuki , Ozawa Tomoko , Yao Tsun-Wen , Shen Wang , Brown Dennis , Parsa Andrew T. , Raizer Jeffrey J. , Cheng Shi-Yuan , Stegh Alexander H. , Mazar Andrew P. , Giles Francis J. , Sarkaria Jann N. , Butowski Nicholas , Nicolaides Theodore , James C. David
Published: April 2023

Supplementary Figure 3: Comparison of U87 and U87vIII viability response to increasing concentrations of NT113
Supplemental Material from Histone Deacetylase 6 Represents a Novel Drug Target in the Oncogenic Hedgehog Signaling Pathway
Authors: Dhanyamraju Pavan Kumar , Holz Philipp Simon , Finkernagel Florian , Fendrich Volker , Lauth Matthias
Published: April 2023

Material lists
Figure S4 from Histone Deacetylase 6 Represents a Novel Drug Target in the Oncogenic Hedgehog Signaling Pathway
Authors: Dhanyamraju Pavan Kumar , Holz Philipp Simon , Finkernagel Florian , Fendrich Volker , Lauth Matthias
Published: April 2023

This file contains supplemental information on Hedgehog pathway induction by HDAC6 inhibitors.
Supplementary Table S3a from Preclinical Test of Dacomitinib, an Irreversible EGFR Inhibitor, Confirms Its Effectiveness for Glioblastoma
Authors: Zahonero Cristina , Aguilera Pilar , Ramírez-Castillejo Carmen , Pajares Marta , Bolós Maria Victoria , Cantero Diana , Perez-Nuñez Angel , Hernández-Laín Aurelio , Sánchez-Gómez Pilar , Sepúlveda Juan Manuel
Published: April 2023

List of primary antibodies.
Supplementary Table S1 from Preclinical Test of Dacomitinib, an Irreversible EGFR Inhibitor, Confirms Its Effectiveness for Glioblastoma
Authors: Zahonero Cristina , Aguilera Pilar , Ramírez-Castillejo Carmen , Pajares Marta , Bolós Maria Victoria , Cantero Diana , Perez-Nuñez Angel , Hernández-Laín Aurelio , Sánchez-Gómez Pilar , Sepúlveda Juan Manuel
Published: April 2023

List of primary GBM cell lines used in this study.
Supplementary Methods from Preclinical Test of Dacomitinib, an Irreversible EGFR Inhibitor, Confirms Its Effectiveness for Glioblastoma
Authors: Zahonero Cristina , Aguilera Pilar , Ramírez-Castillejo Carmen , Pajares Marta , Bolós Maria Victoria , Cantero Diana , Perez-Nuñez Angel , Hernández-Laín Aurelio , Sánchez-Gómez Pilar , Sepúlveda Juan Manuel
Published: April 2023

Detailed description of methods used in this study.
Supplementary Figure 4 from Preclinical Test of Dacomitinib, an Irreversible EGFR Inhibitor, Confirms Its Effectiveness for Glioblastoma
Authors: Zahonero Cristina , Aguilera Pilar , Ramírez-Castillejo Carmen , Pajares Marta , Bolós Maria Victoria , Cantero Diana , Perez-Nuñez Angel , Hernández-Laín Aurelio , Sánchez-Gómez Pilar , Sepúlveda Juan Manuel
Published: April 2023

Analysis of stemmness genes after long term dacomitinib treatment.
Supplementary Figure 4 from Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity
Authors: Jo Jae-Cheol , Choi Eun Kyoung , Shin Jae-Sik , Moon Jai-Hee , Hong Seung-Woo , Lee Ha-Reum , Kim Seung-Mi , Jung Soo-A , Lee Dae-Hee , Jung Seang Hwan , Lee Sun-Hye , Kim Jeong Eun , Kim Kyu-pyo , Hong Yong Sang , Suh Young-Ah , Jang Se Jin , Choi Eun Kyung , Lee Jung Shin , Jin Dong-Hoon , Kim Tae Won
Published: April 2023

Effects of c-MET on phospho-MET and FGFR negative-HCC cell lines.
Supplementary Figure 3 from Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity
Authors: Jo Jae-Cheol , Choi Eun Kyoung , Shin Jae-Sik , Moon Jai-Hee , Hong Seung-Woo , Lee Ha-Reum , Kim Seung-Mi , Jung Soo-A , Lee Dae-Hee , Jung Seang Hwan , Lee Sun-Hye , Kim Jeong Eun , Kim Kyu-pyo , Hong Yong Sang , Suh Young-Ah , Jang Se Jin , Choi Eun Kyung , Lee Jung Shin , Jin Dong-Hoon , Kim Tae Won
Published: April 2023

Effects of MET on the sensitivities of AZD4547-treated HCC cell lines.
Supplementary Figures 1-14; Supplementary Tables 1-3 from A Monoclonal Antibody to ADAM17 Inhibits Tumor Growth by Inhibiting EGFR and Non–EGFR-Mediated Pathways
Authors: Rios-Doria Jonathan , Sabol Darrin , Chesebrough Jon , Stewart Dave , Xu Linda , Tammali Ravinder , Cheng Li , Du Qun , Schifferli Kevin , Rothstein Ray , Leow Ching Ching , Heidbrink-Thompson Jenny , Jin Xiaofang , Gao Changshou , Friedman Jay , Wilkinson Brandy , Damschroder Melissa , Pierce Andrew J. , Hollingsworth Robert E. , Tice David A. , Michelotti Emil F.
Published: April 2023

Supplementary Figures 1-14; Supplementary Tables 1-3. Supplementary Figure 1. Lead antibody 80PH3 is a potent inhibitor of recombinant ADAM17 Supplementary Figure 2. 80PH3 is not a potent inhibitor of cellular ADAM17 Supplementary Figure 3. MEDI3622 is highly selective for ADAM17 and does not inhibit ADAM10 or MMP12 Supplementary Figure 4. MEDI3622 does not compete for binding to cellular ADAM17 with the ADAM17 monoclonal antibody 9301 Supplementary Figure 5. MEDI3622 inhibits cellular mouse ADAM17 Supplementary Figure 6. Cell surface levels of HER pathway proteins in OE21 esophageal cancer cells Supplementary Figure 7. The half-life of MEDI3622 in rats is approximately 8 days Supplementary Figure 8. Several phosphorylation sites in EGFR are inhibited by MEDI3622 Supplementary Figure 9. Exposure to MEDI3622 reduces levels of phospho-SRC and phospho-YES Supplementary Figure 10. Percent activated EGFR predicts cetuximab sensitivity in a series of Head and Neck PDX models Supplementary Figure 11. Proliferation of COLO205 colon cancer cells is independent of the HER pathways Supplementary Figure 12. MEDI3622 does not inhibit HER pathways in Colo205 tumors Supplementary Figure 13. Predictive value of ADAM17, EGFR, HER2, and HER3 mRNA levels for sensitivity of cell lines to MEDI3622 Supplementary Figure 14. Sensitivity to MEDI3622 is not predicted my mRNA levels of ADAM1, HER2 OR HER3 in head and neck PDX models Supplementary Table 1. Correlation of MEDI3622 and cetuximab anti-proliferative activity Supplementary Table 2. Identification of ADAM17 substrates in COLO205 cells by SILAC proteomics Supplementary Table 3. Identification of ADAM17 substrates in H358 lung cancer cells by SILAC proteomics
Supplemental Materials and Methods from Histone Deacetylase Inhibitors Inhibit Rhabdomyosarcoma by Reactive Oxygen Species–Dependent Targeting of Specificity Protein Transcription Factors
Authors: Hedrick Erik , Crose Lisa , Linardic Corinne M. , Safe Stephen
Published: April 2023

Supplemental Material and Methods.
Supplementary Figure Legend from Ingenol Mebutate Signals via PKC/MEK/ERK in Keratinocytes and Induces Interleukin Decoy Receptors IL1R2 and IL13RA2
Authors: Freiberger Sandra N. , Cheng Phil F. , Iotzova-Weiss Guergana , Neu Johannes , Liu Qinxiu , Dziunycz Piotr , Zibert John R. , Dummer Reinhard , Skak Kresten , Levesque Mitchell P. , Hofbauer Günther F.L.
Published: April 2023

Figure legend for supplementary figures.